Cargando…

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma

BACKGROUND: The purpose of this study was to investigate the anti-tumor activities and the mechanisms of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib, combined with the anti-angiogenic target drug apatinib, in the treatment of lung adenocar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Xiong, Zhi-Cheng, Sun, Xin, Sun, Li, Zhang, Shu-Ling, Ma, Jie-Tao, Han, Cheng-Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798075/ https://www.ncbi.nlm.nih.gov/pubmed/35116965 http://dx.doi.org/10.21037/tcr.2019.09.35

Ejemplares similares

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
por: Yi, Xiao-Fang, et al.
Publicado: (2022)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
por: Liu, Yang, et al.
Publicado: (2017)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

Primary resistance to osimertinib despite acquired T790M
por: Chang, Ling‐Kai, et al.
Publicado: (2020)

Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
por: Cao, Yabing, et al.
Publicado: (2019)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
por: Zeng, Yue, et al.
Publicado: (2022)

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2018)

The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
por: Gil, Hyun-Il, et al.
Publicado: (2020)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
por: Kim, Hye Sook, et al.
Publicado: (2023)

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
por: Maeda, Chihiro, et al.
Publicado: (2023)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
por: Xiang, Chan, et al.
Publicado: (2021)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
por: Buzard, Blake, et al.
Publicado: (2023)

The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
por: Miyazaki, Shinichi, et al.
Publicado: (2020)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
por: Li, Chenguang, et al.
Publicado: (2018)

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2018)

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
por: Wang, Nannan, et al.
Publicado: (2019)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
por: Zhou, Rengui, et al.
Publicado: (2021)

Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations
por: Li, Xiao-Feng, et al.
Publicado: (2020)

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
por: Alexeyenko, Andrey, et al.
Publicado: (2022)

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
por: Xia, Leiming, et al.
Publicado: (2021)

Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report
por: Sun, Yanwei, et al.
Publicado: (2020)

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies
por: Miura, Satoru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fqd0srod4hr3jo0pdbiktt10of